ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

on: April 21, 2025In: Evolving Standards of Care
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

In this Q&A, Dr. Luis E. Raez and nurse practitioner Beth Sandy discuss recently reported MARIPOSA data in the context of current standard of care and provide best practices for therapeutic selection and patient education. Read more

ICU Care for the Patient with Lung Cancer

on: April 04, 2019In: Evolving Standards of Care
ICU Care for the Patient with Lung Cancer

By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care […] Read more

Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC

on: April 04, 2019In: Evolving Standards of Care
Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC

Posted: April 1, 2019 Why TMB Should Be Assessed in Patients with Advanced NSCLC By Fabrice Barlesi, MD, PhD Dr. Fabrice Barlesi Immune checkpoint inhibitors, especially PD-1 and PD-L1 inhibitors, have […] Read more

Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer

on: April 04, 2019In: Evolving Standards of Care
Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer

By Russell Bahar, Bsc and Elliot Wakeam, MD, MPH Posted: April 1, 2019 IN REFERENCE TO: Serna-Gallegos DR, et al Effects of time from completed clinical staging to surgery: Does it […] Read more

Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer

on: February 26, 2019In: Evolving Standards of Care
Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer

By Michael MacManus, MD, FRANZCR, and Tim Akhurst, MD, FRACP Posted: March 1, 2019  Dr. Michael MacManus 18F-FDG PET/CT scans portray living biology and are indispensable in thoracic oncologic evaluations, […] Read more

The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management

on: November 08, 2018In: Evolving Standards of Care
The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management

By Andrew R. Haas, MD, PhD Posted: October 2018 Lung cancer remains the leading global cause of cancer-related mortality.1 Due to the lack of symptoms at the time early-stage disease […] Read more

The Treatment of Patients with Oligometastatic Lung Cancer

on: November 08, 2018In: Evolving Standards of Care
The Treatment of Patients with Oligometastatic Lung Cancer

By Anne-Marie C. Dingemans, MD, PhD, and Lizza E.L. Hendriks, MD, PhD Posted: October 2018 Patients with stage IV NSCLC are generally viewed as having incurable disease; however, for years, […] Read more

EGFR TKIs: A Marathon or Sprint?

on: November 08, 2018In: Evolving Standards of Care
EGFR TKIs: A Marathon or Sprint?

By Edgardo S. Santos Castillero, MD, FACP Posted: October 2018 The approval of osimertinib in the frontline setting for patients with EGFR-sensitizing mutations has immediately challenged the decision-making process for […] Read more

CAR-T Cells for Lung Cancer: Q&A with Dr. Charu Aggarwal

on: November 08, 2018In: Evolving Standards of Care
CAR-T Cells for Lung Cancer: Q&A with Dr. Charu Aggarwal

Posted: October 2018 With complete remissions seen in up to 90% of patients with B-cell acute lymphoblastic leukemia (ALL), a breakthrough therapy designation in multiple myeloma, and a first-of-its-kind approval […] Read more

Circulating Tumor Cell–Derived Patient eXplants: A New Tool for SCLC Research

on: August 27, 2018In: Evolving Standards of Care
Circulating Tumor Cell–Derived Patient eXplants: A New Tool for SCLC Research

By Caroline Dive, CBE, PhD, FMedSci, and Kris Frese, PhD Posted: August 2018 Small cell lung cancer (SCLC) is aggressive, disseminates early, and has a dismal prognosis.1 Its genomic landscape […] Read more

The IASLC Issues Liquid Biopsy Statement to Aid Understanding of Rapid Innovation

on: August 27, 2018In: Evolving Standards of Care
The IASLC Issues Liquid Biopsy Statement to Aid Understanding of Rapid Innovation

By Joy Curzio Posted: August 2018 Liquid biopsy is a powerful tool that can determine a patient’s molecular tumor profile and aid diagnosis, as well as therapeutic choices. Liquid biopsy […] Read more

«‹22232425262728›»

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy